Pharmacoepidemiology and Drug Safety, 33(2), 225234
[DOI] [PubMed] [Google Scholar] 99.Knop F.K., Aroda V.R., do Vale R.D., Holst-Hansen T., Laursen P.N., Rosenstock J., Rubino D.M., Garvey W.T., OASIS 1 Investigators Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): A randomised, double-blind, placebo-controlled, phase 3 trial
Targeted peptide and vitamin therapies support recovery, energy, immunity, and tissue repair
[35] reported that a 6-month exenatide-based therapy produced a 42% relative reduction in intrahepatic lipid content, accompanied by a mean BW loss of 5 kg and significant decreases in both abdominal subcutaneous and visceral fat volumes